Blog
RSS FeedPosted by Michael Wonder on 03 Jun 2021
Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents
1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged ...
Posted by Michael Wonder on 18 May 2021
Quebec announces intention to implement a biosimilar switching policy
18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...
Posted by Michael Wonder on 18 May 2021
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...
Posted by Michael Wonder on 18 Nov 2019
Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that ...
Posted by Michael Wonder on 23 Oct 2019
Patients in Quebec now have access to Dupixent for the treatment of moderate-to-severe atopic dermatitis
22 October 2019 - Quebec becomes the first province to list Dupixent for public reimbursement in adult patients. ...
Posted by Michael Wonder on 10 Oct 2019
Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...
Posted by Michael Wonder on 20 Sep 2019
Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer
19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...
Posted by Michael Wonder on 19 Aug 2019
Quebec becomes first province to list Lonsurf (trifluridine/tipiracil) for public reimbursement for adult patients with metastatic colorectal cancer
19 August 2019 - Cancer treatment taken orally shown to extend overall survival in patients whose disease has progressed following treatment ...
Posted by Michael Wonder on 31 Jul 2019
Could Quebec’s public drug plan work for national pharmacare?
30 July 2019 - Quebec’s universal pharmacare program offers better drug coverage and quicker approval for new drugs coming to ...
Posted by Michael Wonder on 25 Jul 2019
Quebec’s public-private pharmacare model provides more generous—and timely—access to new drugs
25 July 2019 - Quebec’s universal pharmacare system, which relies on both a public plan and private insurance providers, covers ...
Posted by Michael Wonder on 14 Feb 2019
Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade
13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...
Posted by Michael Wonder on 16 Feb 2018
Quebec and New Brunswick become first provinces to provide public funding of Ibrance for the first-line treatment of metastatic breast cancer
15 February 2018 - Since Ibrance received Health Canada marketing authorisation in March 2016, Canadian women living with metastatic breast cancer ...